S&P 500   4,219.85 (+0.96%)
DOW   33,064.92 (+0.48%)
QQQ   353.31 (+1.53%)
AAPL   179.93 (+1.51%)
MSFT   333.18 (+1.46%)
META   273.72 (+3.40%)
GOOGL   123.54 (+0.55%)
AMZN   123.37 (+2.31%)
TSLA   209.18 (+2.57%)
NVDA   398.68 (+5.38%)
NIO   7.61 (+1.06%)
BABA   83.23 (+4.63%)
AMD   121.24 (+2.56%)
T   15.87 (+0.89%)
F   12.17 (+1.42%)
MU   69.77 (+2.30%)
CGC   0.83 (-0.38%)
GE   105.07 (+3.49%)
DIS   89.04 (+1.23%)
AMC   4.57 (+1.56%)
PFE   38.07 (+0.13%)
PYPL   63.60 (+2.60%)
NFLX   404.36 (+2.31%)
S&P 500   4,219.85 (+0.96%)
DOW   33,064.92 (+0.48%)
QQQ   353.31 (+1.53%)
AAPL   179.93 (+1.51%)
MSFT   333.18 (+1.46%)
META   273.72 (+3.40%)
GOOGL   123.54 (+0.55%)
AMZN   123.37 (+2.31%)
TSLA   209.18 (+2.57%)
NVDA   398.68 (+5.38%)
NIO   7.61 (+1.06%)
BABA   83.23 (+4.63%)
AMD   121.24 (+2.56%)
T   15.87 (+0.89%)
F   12.17 (+1.42%)
MU   69.77 (+2.30%)
CGC   0.83 (-0.38%)
GE   105.07 (+3.49%)
DIS   89.04 (+1.23%)
AMC   4.57 (+1.56%)
PFE   38.07 (+0.13%)
PYPL   63.60 (+2.60%)
NFLX   404.36 (+2.31%)
S&P 500   4,219.85 (+0.96%)
DOW   33,064.92 (+0.48%)
QQQ   353.31 (+1.53%)
AAPL   179.93 (+1.51%)
MSFT   333.18 (+1.46%)
META   273.72 (+3.40%)
GOOGL   123.54 (+0.55%)
AMZN   123.37 (+2.31%)
TSLA   209.18 (+2.57%)
NVDA   398.68 (+5.38%)
NIO   7.61 (+1.06%)
BABA   83.23 (+4.63%)
AMD   121.24 (+2.56%)
T   15.87 (+0.89%)
F   12.17 (+1.42%)
MU   69.77 (+2.30%)
CGC   0.83 (-0.38%)
GE   105.07 (+3.49%)
DIS   89.04 (+1.23%)
AMC   4.57 (+1.56%)
PFE   38.07 (+0.13%)
PYPL   63.60 (+2.60%)
NFLX   404.36 (+2.31%)
S&P 500   4,219.85 (+0.96%)
DOW   33,064.92 (+0.48%)
QQQ   353.31 (+1.53%)
AAPL   179.93 (+1.51%)
MSFT   333.18 (+1.46%)
META   273.72 (+3.40%)
GOOGL   123.54 (+0.55%)
AMZN   123.37 (+2.31%)
TSLA   209.18 (+2.57%)
NVDA   398.68 (+5.38%)
NIO   7.61 (+1.06%)
BABA   83.23 (+4.63%)
AMD   121.24 (+2.56%)
T   15.87 (+0.89%)
F   12.17 (+1.42%)
MU   69.77 (+2.30%)
CGC   0.83 (-0.38%)
GE   105.07 (+3.49%)
DIS   89.04 (+1.23%)
AMC   4.57 (+1.56%)
PFE   38.07 (+0.13%)
PYPL   63.60 (+2.60%)
NFLX   404.36 (+2.31%)
NASDAQ:ADAG

Adagene (ADAG) Stock Forecast, Price & News

$1.35
+0.03 (+2.27%)
(As of 03:14 PM ET)
Compare
Today's Range
$1.30
▼
$1.37
50-Day Range
$1.29
▼
$1.52
52-Week Range
$0.90
▼
$2.87
Volume
3,304 shs
Average Volume
18,263 shs
Market Capitalization
$58.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Adagene MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
266.6% Upside
$5.00 Price Target
Short Interest
Healthy
0.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Adagene in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.92) to ($2.05) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

1139th out of 1,980 stocks

Pharmaceutical Preparations Industry

563rd out of 978 stocks

See Top Rated MarketRank™ Stocks Here

ADAG stock logo

About Adagene (NASDAQ:ADAG) Stock

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

ADAG Stock News Headlines

May 28, 2023 | americanbankingnews.com
Short Interest in Adagene Inc. (NASDAQ:ADAG) Grows By 108.5%
May 25, 2023 | finance.yahoo.com
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
June 1, 2023 | Edge On The Street (Ad)
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
May 23, 2023 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: Poseida Therapeutics (PSTX), Mustang Bio (MBIO)
May 16, 2023 | americanbankingnews.com
Adagene Inc. (NASDAQ:ADAG) Sees Large Decrease in Short Interest
May 4, 2023 | finance.yahoo.com
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
April 30, 2023 | americanbankingnews.com
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 28.8% in April
April 28, 2023 | finance.yahoo.com
Adagene Announces Updates to its Board of Directors
June 1, 2023 | Edge On The Street (Ad)
ChatGPT Is Already "Old School"
As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.
April 24, 2023 | americanbankingnews.com
Adagene (NASDAQ:ADAG) Given Buy Rating at HC Wainwright
April 24, 2023 | americanbankingnews.com
Adagene's (ADAG) Buy Rating Reiterated at HC Wainwright
April 22, 2023 | msn.com
HC Wainwright & Co. Reiterates Adagene Inc - ADR (ADAG) Buy Recommendation
April 21, 2023 | markets.businessinsider.com
Expert Ratings for Adagene
April 18, 2023 | finance.yahoo.com
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
April 18, 2023 | americanbankingnews.com
Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest
April 1, 2023 | americanbankingnews.com
Adagene Inc. (NASDAQ:ADAG) Sees Significant Increase in Short Interest
March 31, 2023 | msn.com
Are Medical Stocks Lagging Adagene (ADAG) This Year?
March 31, 2023 | finance.yahoo.com
Are Medical Stocks Lagging Adagene (ADAG) This Year?
March 31, 2023 | finance.yahoo.com
Adagene Full Year 2022 Earnings: US$1.85 loss per share (vs US$1.83 loss in FY 2021)
March 31, 2023 | americanbankingnews.com
Adagene Inc. (NASDAQ:ADAG) to Post FY2023 Earnings of ($1.49) Per Share, HC Wainwright Forecasts
March 31, 2023 | americanbankingnews.com
HC Wainwright Reiterates "Buy" Rating for Adagene (NASDAQ:ADAG)
March 29, 2023 | finanznachrichten.de
Adagene Inc.: Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
March 28, 2023 | finance.yahoo.com
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
March 21, 2023 | americanbankingnews.com
Adagene (NASDAQ:ADAG) Receives Buy Rating from HC Wainwright
March 21, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for Adagene (ADAG)
March 16, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Hookipa Pharma (HOOK)
March 14, 2023 | finance.yahoo.com
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
See More Headlines

ADAG Price History

ADAG Company Calendar

Today
6/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADAG
CUSIP
N/A
CIK
1818838
Web
www.adagene.com
Phone
86-512-8777-3632
Fax
N/A
Employees
198
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+266.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
2.71
Quick Ratio
2.71

Sales & Book Value

Annual Sales
$9.29 million
Price / Sales
6.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.91 per share
Price / Book
0.71

Miscellaneous

Outstanding Shares
43,250,000
Free Float
34,083,000
Market Cap
$58.98 million
Optionable
Not Optionable
Beta
0.05

Key Executives

  • Dr. Peter P. Luo Ph.D. (Age 56)
    Co-Founder, CEO & Chairman
  • Mr. Man Kin Tam M.B.A. (Age 45)
    CFO & Director
  • Dr. Fangyong Du Ph.D. (Age 52)
    Chief Technology Officer
  • Dr. Jc Xu M.D. (Age 57)
    Ph.D., Chief Scientific Officer
  • Ms. Ami Celeste Knoefler
    VP of Investor Relations & Corp. Communications
  • Ms. Ling Zhou
    Head of HR
  • Dr. Qinghai Zhao (Age 61)
    Chief Manufacturing Officer
  • Ms. Yan Li M.B.A. (Age 47)
    Sr. VP of Bioinformatics & Information Technology
  • Ms. Xiaohong She (Age 55)
    Sr. VP & Head of Clinical Operations
  • Dr. Guizhong Liu Ph.D. (Age 51)
    Head of Biology & Pharmacology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ADAG Stock - Frequently Asked Questions

Should I buy or sell Adagene stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADAG shares.
View ADAG analyst ratings or view top-rated stocks.

What is Adagene's stock price forecast for 2023?

2 brokerages have issued twelve-month price objectives for Adagene's shares. Their ADAG share price forecasts range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 266.6% from the stock's current price.
View analysts price targets for ADAG or view top-rated stocks among Wall Street analysts.

How have ADAG shares performed in 2023?

Adagene's stock was trading at $1.3250 at the start of the year. Since then, ADAG stock has increased by 2.9% and is now trading at $1.3638.
View the best growth stocks for 2023 here.

Are investors shorting Adagene?

Adagene saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 19,600 shares, an increase of 108.5% from the April 30th total of 9,400 shares. Based on an average daily volume of 10,700 shares, the days-to-cover ratio is presently 1.8 days. Approximately 0.1% of the shares of the stock are short sold.
View Adagene's Short Interest.

When did Adagene IPO?

(ADAG) raised $133 million in an initial public offering on Tuesday, February 9th 2021. The company issued 7,400,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager.

What is Adagene's stock symbol?

Adagene trades on the NASDAQ under the ticker symbol "ADAG."

Who are Adagene's major shareholders?

Adagene's stock is owned by many different retail and institutional investors. Top institutional investors include Strategic Vision Investment Ltd (0.81%) and Renaissance Technologies LLC (0.09%).

How do I buy shares of Adagene?

Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adagene's stock price today?

One share of ADAG stock can currently be purchased for approximately $1.36.

How much money does Adagene make?

Adagene (NASDAQ:ADAG) has a market capitalization of $58.98 million and generates $9.29 million in revenue each year.

How many employees does Adagene have?

The company employs 198 workers across the globe.

How can I contact Adagene?

Adagene's mailing address is 4F BUILDING C14 NO. 218 XINGHU STREET SUZHOU INDUSTRIAL PARK, JIANGSU F4, 215123. The official website for the company is www.adagene.com. The company can be reached via phone at 86-512-8777-3632 or via email at ir@adagene.com.

This page (NASDAQ:ADAG) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -